MedTrace Logo

A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer

NCT03587285 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-08-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility, safety and oncological efficacy of hormonal therapy combined with autologous Tcm cells for patients with advanced prostate cancer.

Conditions

  • Prostatic Neoplasms

Interventions

BIOLOGICAL

Tcm+ Goserelin acetate+ Bicalutamide

Autologous Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,50 mg bicalutamide administered orally daily

BIOLOGICAL

Tcm+Goserelin acetate+Abiraterone acetate

Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,1000 mg abiraterone acetate administered orally daily plus 5 mg prednisone administered orally twice daily

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • Guangzhou University of Traditional Chinese Medicine

    lead OTHER

Principal Investigators

  • Songtao Xiang, MD · Guangzhou University of Chinese Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-23
Primary Completion
2021-07-30
Completion
2021-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03587285 on ClinicalTrials.gov